Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Dermatology
•
Systemic autoimmune diseases
Do you see a role for early, aggressive treatment for MCTD to prevent progression of disease, even though there has not been end-organ manifestations?
Related Questions
What treatments have you found most effective for cholestatic pruritus?
How do you approach managing nausea and GI side effects when initiating methotrexate?
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach for severe SCLE in patients unable to tolerate HCQ?
What therapies have you found most effective for JAK-induced/associated acne (JAKcne)?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?
